ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Axitinib

Also written as “AG-013736”, “axitinib” and “OTX-TKI”.

Its studies are mostly in Carcinoma, Renal Cell · Carcinoma, Non-Small-Cell Lung · Macular Degeneration · Neoplasms · Carcinoma, led by 6 companies.

Drug pageAxitinib: every studyMany companies study it; this page follows only the 45 they lead. All 139 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since May 7, 200745 company-led studies, 4 open or runningNext primary completion: Jan 8, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizerits history only360 open or runningphase 3since May 7, 2007Oct 9, 2003none ahead
Ocular Therapeutix54 open or runningphase 3since Jan 12, 2024Jun 1, 2018Jan 8, 2027phase 3 · NCT06495918
Arog Pharmaceuticalsits history only10 open or runningphase 2since Oct 6, 2006Oct 6, 2006none ahead
Merckits history only10 open or runningphase 3since Jul 29, 2016Jul 29, 2016none ahead
SFJ Pharma Ltd. IIits history only10 open or runningphase 3since May 11, 2012May 11, 2012none ahead
Strata Oncologyits history only10 open or runningphase 2since Oct 1, 2021Oct 1, 2021none ahead

Also a collaborator on its studies: Fortrea, Gilead Sciences and SFJ Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Ocular Therapeutix only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 1, 2018First study: phase 1 study in Neovascular Age-related Macular DegenerationFirst studyNCT03630315 · 29 enrolled · Australia
  2. Jan 5, 2023Phase 1 study in Non-proliferative Diabetic RetinopathyNCT05695417 · 21 enrolled · United States
  3. Jan 12, 2024Phase 3 study in Neovascular Age-Related Macular DegenerationNCT06223958 · 344 enrolled · United States, Argentina, Puerto Rico
  4. Jul 3, 2024Phase 3 study in Neovascular Age-related Macular DegenerationNCT06495918 · 825 enrolled · United States, Argentina, Australia and more
  5. Mar 31, 2026Phase 3 study in Neovascular Age-Related Macular Degeneration (nAMD)NCT07516132 · 850 planned · United States

Ahead

  1. Jan 8, 2027Primary completion: phase 3 study in Neovascular Age-related Macular DegenerationNCT06495918
  2. Aug 1, 2030Primary completion: phase 3 study in Neovascular Age-Related Macular Degeneration (nAMD)NCT07516132

TargetBeta

“Vascular endothelial growth factor receptor inhibitor”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
lenvatinibruleEisaiphase 481
nintedanibruleBoehringer Ingelheimphase 476
regorafenibruleBayerphase 440
chiauranibruleChipscreen Biosciencesphase 315

Studies

All 5 Ocular Therapeutix leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07516132Neovascular Age-Related Macular Degeneration (nAMD) · United States3RecruitingAug 1, 2030850
NCT06495918Neovascular Age-related Macular Degeneration · United States, Argentina, Australia and more3Active, not recruitingJan 8, 2027825
NCT06223958Neovascular Age-Related Macular Degeneration · United States, Argentina, Puerto Rico3Active, not recruitingApr 29, 2026344
NCT05695417Non-proliferative Diabetic Retinopathy · United States1Active, not recruitingJan 202421
NCT03630315Neovascular Age-related Macular Degeneration · Australia1CompletedJan 10, 202429

How it is read

Names in the registry

  • “AG-013736”, 23 entries
  • “axitinib”, 13 entries
  • “OTX-TKI”, 8 entries
  • “Axitinib (AG-013736)”, 8 entries
  • “AG-013736 (axitinib)”, 7 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.